EC Considers API Regulation In Effort To Fight Counterfeit Drugs

Stricter requirements for active ingredients, a ban on repackaging, and mandatory company audits of their trading partners are on the table in the European Commission's quest for antidotes to a growing influx of counterfeit medicines